Ypsomed Holding AG

Equities

YPSN

CH0019396990

Medical Equipment, Supplies & Distribution

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
337.5 ^CHF	-0.44%		-11.18%	+11.39%

Apr. 16	Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization	MT
Apr. 12	Dental Equipment Company Straumann Names New Chair	MT

Ypsomed Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023

November 15, 2023 at 02:48 pm EST

Ypsomed Holding AG reported earnings results for the half year ended September 30, 2023. For the half year, the company reported net income was CHF 36.58 million compared to CHF 15.44 million a year ago. Basic earnings per share from continuing operations was CHF 2.68 compared to CHF 1.17 a year ago.

Latest news about Ypsomed Holding AG

Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization	Apr. 16	MT
Dental Equipment Company Straumann Names New Chair	Apr. 12	MT
Gerresheimer expects sales boost from burgeoning obesity drugs sector	Apr. 11	RE
Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says	Mar. 29	RE
Swiss Equities Rise as Economic Sentiment Further Brightens	Mar. 27	MT
Ypsomed to Sell Pen Needle, Glucose Monitoring Units Amid Increased Focus on Diabetes Care	Mar. 27	MT
MTD Medical Technology and Devices S.A. agreed to acquire the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG.	Mar. 26	CI
Octavian Downgrades Recommendation on Ypsomed to Hold From Buy	Feb. 26	MT
Switzerland's Sonova Names New Chair for 2025 Nomination	Nov. 17	MT
Ypsomed Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 15	CI
Transcript : Ypsomed Holding AG, H1 2024 Earnings Call, Nov 15, 2023	Nov. 15
Ypsomed Posts Growth in Fiscal H1 Net Profit, Sales	Nov. 15	MT
How Novo Nordisk makes its weight-loss drug Wegovy	Nov. 01	RE
Ypsomed to Customize, Supply Autoinjector Pen Device for Viridian Therapeutics	23-10-26	MT
Viridian Therapeutics, Inc. Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed Ag for Subcutaneous Drug Delivery in Thyroid Eye Disease	23-10-26	CI
Ypsomed Signs Partnership to Offer Human Factor Services	23-10-05	MT
Ypsomed Appoints Feintool CFO to Same Role	23-09-29	MT
Health Care Climbs on Defensive Bias -- Health Care Roundup	23-09-20	DJ
Novo Nordisk, Ypsomed Conclude Long-Term Autoinjector Supply Deal	23-09-20	MT
Correction to Ypsomed Article	23-09-20	DJ
Ypsomed to Supply Novo Nordisk With Autoinjectors	23-09-20	DJ
Ypsomed signs autoinjector supply deal with Novo Nordisk	23-09-20	RE
Ypsomed Signs Long-term Autoinjectors Supply Contract with Novo Nordisk	23-09-20	MT
Dental implants maker Straumann reports H1 sales in line with expectations	23-08-15	RE
SIX Group Makes Index Adjustments Following Review	23-07-11	MT

Chart Ypsomed Holding AG

Duration

Period

More charts

Company Profile

Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-21 - Q4 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for Ypsomed Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

337.5 CHF

Average target price

351.3 CHF

Spread / Average Target

+4.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
YPSOMED HOLDING AG	+11.39%	5.04B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution